A Trial of SHR-1703 in Asthma

Summary

SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in patients with asthma. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics ，pharmacodynamics and immunogenic characteristics of multiple subcutaneous injections of SHR-1703 in asthmatic patients.

Timeline

Start

2021-10-12

Primary completion

2023-06-15

Completion

2023-06-15

Drugs

Indications